TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04853342: A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, Study to Assess the Efficacy and Safety of Furmonertinib (AST2818) Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positi

Sponsor: Allist Pharmaceuticals, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 318 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT04853342 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04853342 Rescue Dossier →